DAY 1, 15 June 2026

TIME PROGRAMME MODERATOR / SPEAKERS
0800 – 0845 Registration
0845 – 0900 Welcome Address Eng Eong Ooi,
Co-organiser, 9th ADS
0900 – 0930 Keynote Lecture: Back to the future – Lessons for dengue research from the HIV field Nelson Michael,
WRAIR, USA
0930 – 1040 Symposium 1: Setting the stage Moderator:
Jarir At Thobari
Why is dengue surging globally? Henrik Salje,
Cambridge University
Dengue vaccines – Lessons learned from the pursuit of perfection Stephen Thomas,
SUNY Upstate
Will Wolbachia be a public health success: Evidence from Brazil Albert Ko,
Yale University
Short talk: Integrating global dengue surveillance to give insights into climactic drivers, growth trends, outbreak forecasting Oliver Brady,
LSHTM, UK
1040 – 1100 Tea Break
1100 – 1230 Symposium 2: Lessons from the field Moderator:
Eng Eong Ooi
Arbovirus surveillance and molecular epidemiology Nuno Faria,
Imperial College, London
Dengue, climate change, and mitigation approaches Borame Dickens,
SSHSPH, Singapore
Community dengue spread: implications for interventions Martin Hibberd,
LSHTM, UK
Acceptability and barriers to dengue vaccination Hannah Clapham,
SSHSPH, Singapore
Short talk: Stepwise approach for dengue vaccine introduction to National Immunization Programme in Thailand Anyarat Thamjaroen,
National Vaccine Institute, Thailand
1230 – 1330 Lunch
1330 – 1445 Industry Symposium A (Takeda): From Vaccine To Vaccine-nations – Solutions For Dengue Prevention
Welcome Tikki Pangestu
TAK-003 The Comprehensive Clinical Development & Global Vaccine Experience Derek Wallace
Country perspectives in vaccine implementation in public and private settings Moderator:
Choo Beng Goh

Speakers:
Julio Croda
Thanyawee Puthanakit
Turning Insights into Action: Panel Discussion on Dengue Prevention Moderator:
Choo Beng Goh

Panelists:
Derek Wallace
Julio Croda
Thanyawee Puthanakit
Tikki Pangestu
Key Takeaways and Close Tikki Pangestu
1445 – 1540 Symposium 5: A dengue drug – why we need one and how we get there (I) Moderator:
Jenny Low
Current state of play of dengue therapeutic development Andre Siqueira,
DNDi
Adaptive platform trials for dengue therapeutics Sophie Yacoub,
Oxford University
Short talk: Anakinra for dengue patients with hyperinflammation: a phase II double-blind randomized controlled trial Huyen Bang Tran
OUCRU, Vietnam
1540 – 1600 Tea Break
1600 – 1720 Symposium 3: New Challenges- from Virus evolution to climate change Moderator:
Kevin Tetteh
Collective Action on Dengue Kevin Tetteh,
CAD
Dengue virus genetics and Wolbachia Chantal Vogels,
Yale University
Single amino acid change on E protein prevents IgM-mediated neutralization during DENV2 infection Sylvie Alonso,
NUS, Singapore
Host-virus interactions in dengue Laura Martin-Sancho,
Imperial College, London
Flavivaccine: Targeting mosquito saliva factors blocks flavivirus transmission and disease Julien Pompon,
IRD, France
1720 – 1745 Break
1745 – 1845 World Dengue Day Session
Welcome Remarks Marianne Comparet,
ISNTD
Opening Remarks Janil Puthucheary,
Senior Minister of State for Sustainability and the Environment, Singapore
Online Statements from Around the Globe: Messages of support and perspectives from International partners and representatives
Panel Discussion Janil Puthucheary,
Senior Minister of State for Sustainability and the Environment, Singapore

Florika Fink-Hooijer
Director General Health Emergency Preparedness & Response HERA, European Commission

Diana Rojas Alvarez
Head (a.i.) Emerging Zoonosis and High Impact Epidemics Unit, WHO

Julio Croda
Federal University of Mato Grosso do Sul, Yale School of Public Health, and Oswaldo Cruz Foundation
Group Photo for the Panelists
MOU Announcement Asia Dengue Voice & Action Group (ADVA)

Dengue Prevention Advocacy Malaysia (DPAM)

Empowering Networks to Defeat Dengue (E.N.D. Dengue Coalition)

Koalisi Bersama Lawan Dengue (Joint Coalition Against Dengue – KOBAR)
Group Photo for MOU Partners
Close of Day 1

DAY 2, 16 June 2026

TIME PROGRAMME MODERATOR / SPEAKERS
0820 – 0830 Welcome Back Lee Ching Ng
0830 – 0945 Symposium 6: Dengue immunity (I) – what protects and what makes us sick? Moderator:
Sylvie Alonso
Pathogenesis of severe dengue beyond ADE Adam Waickman,
SUNY Upstate
Contributions of circulating & skin-resident T cells to protective immunity in dengue Laura Rivino,
Liverpool School of Tropical Medicine
De-risking ADE, Revealing Mechanism: Fusion Loop-Mutated prM/E Zika Vaccines Protect via CD8 T Cells, but Not Durably Sujan Shresta,
La Jolla Institute of Immunology, USA
Systems immunology approaches to uncover features associated with severe disease during primary dengue virus infection Diana S. Hansen,
Monash University
Immune response in asymptomatic dengue Ponpan Matangkasombut Choopong,
Mahidol University
0945 – 1005 Tea Break
1005 – 1120 Symposium 8: Dengue immunity (II) – what protects and what makes us sick? Moderator:
Shirin Kalimuddin
Correlates of protection and risk in dengue: lessons from cohort studies Leah Katzelnick,
NIH, USA
Short talk: Prior Zika virus imprints subsequent dengue virus neutralizing antibodies by skewing the repertoire of antibody-secreting cells Tulika Singh,
UC Berkeley, USA
Short talk: Is homotypic reinfection a key feature of dengue endemic settings? Jair Andrade,
University of Cambridge, UK
Short talk: Mechanistic insights into dengue virus-induced reprogramming of innate immune response Usama Ashraf,
Duke-NUS
1120 – 1235 Symposium 7: Emerging challenges in dengue management Moderator:
Rose Capeding
Dengue and obesity Neelika Malavige,
Sri Jayewardenepura University, Sri Lanka
Clinical predictors and determinants of severe disease Nguyen Lam Vuong,
OUCRU, Vietnam
Post-acute burden of dengue Wee Liang En Ian,
SGH, Singapore
Real-time continuous clinical monitoring for dengue Ho Quang Chanh,
OUCRU, Vietnam
1235 – 1335 Lunch
1335 – 1440
ADVA Educational Symposium 1: Innovations for Aedes-borne disease control
(Supported by: Bavarian-Nordic & World Mosquito Program)		 Moderator:
Lulu Bravo
Global evidence base for vector control Jue Tao Lim,
NTU, Singapore
Updates from World Mosquito Program Bekti Andari,
World Mosquito Program
Updates on Chikungunya Tsin Wen Yeo,
NTU, Singapore
1440 – 1630 Poster Session (and tea break served at 1600)
1630 – 1740 Symposium 9: A dengue drug – why we need one and how we get there (II) Moderator:
Zulkifli Ismail
Clinical management for zero dengue deaths: How can we do better? Giri Shan Rajahram,
QEII Hospital, Malaysia
Update on ISLA-101 development David Foster,
Island Pharma
Short talk: A role for sphingosine-1-phopshate analogues in dengue shock? Angela McBride,
Oxford University
WHO Dengue TPP Xin Hui Chan
Panel Discussion / Q&A Andre Siqueira,
Giri Shan Rajahram,
David Foster,
Xin Hui Chan,
Angela McBride
1740 Close of Day 2

DAY 3, 17 June 2026

TIME PROGRAMME MODERATOR / SPEAKERS
0730 Registration starts
0815 – 0820 Welcome Back Eng Eong Ooi
0820 – 0950 ADVA-JA Dengue Slayers Challenge
0950 – 1010 Tea Break
1010 – 1115 Symposium 10: New developments in dengue vaccines Moderator:
Ignacio Esteban
GAVI and dengue vaccines Ignacio Esteban,
GAVI
Updates from TAK-003 Booster Trial data Shibadas Biswal,
Takeda
Development of a live-attenuated tetravalent dengue vaccine (KD-382) Motoharu Abe,
KM Biologics
Updates on V181 phase 3 clinical trial Soumya Chatterjee,
MSD
1115 – 1215 ADVA Educational Symposium II: New tools to combat dengue
Supported by: Roche, Sysmex, ProImmune
Advancing Dengue Diagonstics: Leveraging Antigen and IgM Immunoassays with Automation to Overcome Diagnostic Challenges Carolin Bier,
Roche
Antigen-specific T cell characterisation and immune monitoring tools & Ankyrons® – Next generation target binding and detection Chua WenZhe,
ProImmune
1215 – 1315 Lunch
1315 – 1410 Symposium 11: Interrupting dengue transmission Moderator:
Shuzhen Sim
Long terms outcomes of Wolbachia Aedes Replacement Eggi Arguni,
Universitas Gadjah Mada, Indonesia
Wolbachia Aedes suppression for dengue control Milly Choy,
NEA, Singapore
Short talk: Strategic deployment of wMEL-SG for suppression of wALB-SG populations established in the field Li Yun Tan,
NEA, Singapore
1410 – 1525 Symposium 12: Real-world evidence in dengue control Moderator:
Jue Tao Lim
Gaps in Real-world Evidence generation Derek Cummings,
Johns Hopkins University
Real world evidence of dengue vaccination in Brazil Julio Croda,
Universidade Federal de Mato Grosso do Sul, Brazil
Effectiveness of integrated dengue control measures Nurulhusna Ab Hamid,
MOH, Malaysia
Public Health impact and cost-effectiveness of dengue vaccination Jing Shen,
Takeda
1525 – 1545 Tea Break
1545 – 1700 Symposium 13: Innovative Solutions for Dengue
– Urban Planning
– Community-based care
– Innovative Financing
Panel Discussion Tikki Pangestu
YLL School of Medicine, NUS

Graham Alabaster
Former Director, UN-Habitat

Michelle Tan
SGH, Singapore

Patsian Low
Asia Venture Philanthropy Association (AVPN)

A. Vigneswari
For APEC Dengue Roadmap (Crowell Global Advisors)
1700 – 1720 Award Ceremony and Closing Lee Ching Ng
SPEAKER COUNTRY DESIGNATION
Nelson Michael USA Director, Center for Infectious Diseases
Research Walter Reed Army Institute of Research
Henrik Salje UK Department of Genetics,
University of Cambridge
Martin Hibberd UK Faculty of Infectious & Tropical Disease
London School of Hygiene and Tropical Medicine
Tahmina Shirin Bangladesh Director, Institute of Epidemiology, Disease Control & Research
Ian Liang En Wee Singapore Consultant
Singapore General Hospital
Jing Shen UK Director, Health Economics & Modelling, Global Vaccine Business unit
Takeda Pharmaceuticals International AG
Laura Rivino UK School of Cellular and Molecular Medicine
University of Bristol
Adam Waickman USA Department of Microbiology and Immunology
Upstate Medical University
Diana Hansen Australia Associate Director (International), Biomedicine Discovery Institute
Co-Head Infection Discovery Program Monash University
Sujan Shresta USA Center for Infectious Disease and Vaccine
Research La Jolla Institute for Immunology
Leah Katzelnick USA Viral Epidemiology and Immunity
Unit National Institutes of Health
Sylvie Alonso Singapore National University of Singapore
Chantal Vogels USA Department of Epidemiology of Microbial
Diseases Yale School of Public Health
Nuno Faria UK Department of Infectious Disease
Epidemiology Imperial College London
Sophie Yacoub UK Oxford University Clinical Research Unit
(OUCRU) Ho Chi Minh City
Laura Martin-Sancho UK Department of Infectious Disease
Imperial College London
Julien Pompon France iHAT (Inter-Host Arbovirus Transmission) Team Leader
The Institut de recherche pour le developpement (IRD)
Nguyen Lam Vuong Vietnam Oxford University Clinical Research Unit (OUCRU)
Giri Rajahram Malaysia Head of the Department of Medicine,
Queen Elizabeth II Hospital
Neelika Malavige Sri Lanka Department of Immunology and Molecular Medicine
University of Sri Jayewardenepura
Julio Croda Brazil Universidade Federal de Mato Grosso do Sul
Hannah Clapham Singapore Saw Swee Hock School of Public Health
National University of Singapore
Derek Cummings USA Johns Hopkins Bloomberg School of Public Health
Stephen Thomas USA Director, Upstate Global Health I
nstitute SUNY Upstate Medical University
Shibadas Biswal USA Head, Clinical Science, Vaccine Business
Takeda Pharmaceuticals International AG
Motoharu Abe Japan Project Leader, KM Biologics Co Ltd
Milly Choy Singapore National Environment Agency
Eggi Arguni Indonesia Faculty of Medicine
Universitas Gadjah Mada
Nurulhusna Binti Ab Hamid Malaysia Institute for Medical Research (IMR)
Borame Dickens Singapore Saw Swee Hock School of Public Health
National University of Singapore
Ho Chanh Quang Vietnam Head of Dengue Research Group
Oxford University Clinical Research Unit (OUCRU)
Albert Ko USA Department of Epidemiology of Microbial Diseases
Yale School of Public Health
Ponpan Matangkasombut Thailand Department of Microbiology, Faculty of Science
Mahidol University

14 June 2026

Dengue Prevention – 7 Years of TAK-003 Clinical Experience, Real World Evidence Advancement and Beyond

TIME ACTIVITY ACTIVITY
1200 – 1300 Lunch available for participants
1300 – 1315 Welcome and Global Context Setting Shirin Kalimuddin
1315 – 1355 Long Term Clinical Evidence for TAK-003 Speaker:
Eduardo Lopez Medina

Q&A Panel:
Eduardo Gomensoro,
Shibadas Biswal,
Eng Eong Ooi,
Eduardo Lopez Medina
1355 – 1445 Real-World Evidence: Safety and Effectiveness Across Diverse Settings Speaker:
Julio Croda
Pablo Bonvehi
Marcelo Franco/ Vianney Tricou
1445 – 1500 Tea Break
1500 – 1555 DEN-Talk (immunology chapter)

  1. Correlates of Protection: Why Dengue Is Different – Eng Eong Ooi
  2. Dengue infection elicits skin tissue-resident T cells– Laura Rivino
  3. Innate Immune Reprogramming and Emerging Concepts– Eng Eong Ooi
  4. Dichotomy between nAb and T cells– Shirin Kalimuddin
  5. TAK-003 immunogenicity – in the context of emerging evidence on protective immunity– Mayuri Sharma
 Speaker:
Eng Eong Ooi
Laura Rivino
Shirin Kalimuddin
Mayuri Sharma


Q&A Panel:
Mayuri Sharma (Chair & panellist),
Eng Eong Ooi,
Laura Rivino,
Shirin Kalimuddin
1555 – 1650 Expert Panel Discussion:

  • Dengue Surveillance and Epidemiology; Integrated Dengue Prevention Framework; Country experiences, NIP, Public programmes; What’s the best way to deliver TAK-003 in public programmes.
  • Questions from participants via Slido
 Panel:
Eduardo Lopez Medina (Chair & panellist), Wanatpreeya Phongsamart, Jarir At Thobari
1650 – 1700 Key Takeaways and Close Shirin Kalimuddin

18 June 2026

ASIA WOLBACHIA DIALOGUE 2026

Organized by Asian Development Bank (ADB), in collaboration with, Singapore National Environment Agency (NEA), and Indonesia Ministry of Health (Kemenkes), and Asia Dengue Voice & Action (ADVA)

TIME ACTIVITY SPEAKERS
0800 – 0815 Registration
0815 – 0845 Welcome and Overview
– NEA
– ADB
– Indonesia MoH
– ADVA		 Lee Ching Ng,
NEA Singapore

Eduardo Banzon,
Director, Health, ADB

Andi Saguni,
Acting DG, Communicable Disease Control, Indonesia MOH

Zulkifli Ismail,
ADVA
0845 – 0855 Keynote Speech 1 Hon. Budi Sadikin,
Minister of Health, Republic of Indonesia
0855 – 0905 Keynote Speech 2 Md. Quamruzzaman Chowdhury,
Secretary, Health Services, Ministry of Health & Family Welfare, Bangladesh
0905 – 0925 Wolbachia: WHO Policy and Guidance Lauren Carrington,
Technical Officer, WHO
0925 – 0950 Epidemiological evidence supporting Wolbachia as an intervention and its benefits Lim Jue Tao & Jo Yi Chow,
Nanyang Technological University, Singapore
0950 – 1015 Tea Break
1015 – 1100 Brief Overview: Wolbachia Approaches

Panel Discussion: Practical considerations for selecting Replacement v Suppression approaches

 Moderator:
Lee Ching Ng,
Group Director, NEA SingaporePanelists:

Peter Ryan,
Director, Technical Engagement, World Mosquito Program

Zhiyong Xi,
Michigan State University / Wolbaki

Florence Fouque,
Ex-WHO TDR, Affiliated Scientist, Institute of Microbiology, SUPSI Switzerland

Katie Anders,
Associate Professor (Research) and NHMRC Emerging Leadership Fellow, Monash University
1100 – 1130 Wolbachia Operational Delivery Models Jenny Zhang,
Regional Senior Associate, Dengue, Clinton Health Access Initiative
1130 – 1200 Investment Case for Wolbachia Aman Singh,
Senior Social Sector Specialist, Health, ADB

Oliver Brady,
Professor of Spatial Epidemiology and Lead of Centre for Mathematical Modelling of Infectious Diseases, LSHTM UK
1200 – 1320 Lunch
1320 – 1500 Wolbachia Implementation Overview – Asia and Pacific

Country Journeys and Plans:
• Brazil
• Singapore
• Indonesia
• Malaysia
• Lao PDR

Q&A

 James F. Kelley,
Technical Officer, WPRO

Country/Government Representatives
1500 – 1515 Tea Break
1515 – 1510 Wolbachia Implementers’ Session

Q&A

 WMP
Flyttr
Debug
SymbioCI SEA
1610 – 1655 Donor Panel Discussion

Q&A

 Moderator:
Martin Edlund,
CEO Billion Scale HealthPanelists:

Eduardo Banzon,
Director, Health, ADB

Sasha Lee,
Assistant Director, Pacific Health Section, DFAT

Fook Kay Lee,
Director, Pandemic Preparedness, Temasek Foundation

Rahul Chandran,
Chief Strategy and Partnerships Officer, Grand Challenges Canada (TBC)

Kapila Kannangara,
Acting Director, National Dengue Control Unit, Sri Lanka
1655 – 1700 Closing Remarks ADB and ADVA